Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vudalimab Alone or in Combination With Chemotherapy or Targeted Therapies in mCRPC
NCT05005728Phase 2Completed
- Sponsor
- Xencor
- Start
- Oct 2021
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vudalimab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Xencor. Started Oct 2021; status: completed.
02
Drugs
vudalimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05005728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005728.